Literature DB >> 7837204

Potency equivalence of botulinum toxin preparations.

P Hambleton, A M Pickett.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7837204      PMCID： PMC1294955     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  1 in total

1.  Dose standardisation of botulinum toxin.

Authors:  N Quinn; M Hallett
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321
  1 in total
  15 in total

1.  Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.

Authors:  Dirk Dressler; Gerd Mander; Klaus Fink
Journal:  J Neural Transm (Vienna)       Date:  2011-10-05       Impact factor: 3.575

2.  Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study.

Authors:  K Wohlfarth; I Schwandt; F Wegner; T Jürgens; G Gelbrich; A Wagner; U Bogdahn; W Schulte-Mattler
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

Review 3.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 4.  Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.

Authors:  Roberta Ravenni; Domenico De Grandis; Alberto Mazza
Journal:  Neurol Sci       Date:  2013-04-11       Impact factor: 3.307

5.  Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport.

Authors:  Katja Kollewe; Bahram Mohammadi; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-05-01       Impact factor: 3.575

6.  Dose standardisation of botulinum toxin.

Authors:  M H Marion; M Sheehy; S Sangla; S Soulayrol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-07       Impact factor: 10.154

7.  A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.

Authors:  T Odergren; H Hjaltason; S Kaakkola; G Solders; J Hanko; C Fehling; R J Marttila; H Lundh; S Gedin; I Westergren; A Richardson; C Dott; H Cohen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

8.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

Review 9.  Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?

Authors:  Avram Fraint; Padmaja Vittal; Cynthia Comella
Journal:  Ther Clin Risk Manag       Date:  2016-02-05       Impact factor: 2.423

Review 10.  Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.

Authors:  Francesco Scaglione
Journal:  Toxins (Basel)       Date:  2016-03-04       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.